Related Experiment Video
Updated: Apr 21, 2026
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
Cardiomyocyte-specific role of miR-24 in promoting cell survival
Chuner Guo1, Yangmei Deng, Jiandong Liu
1Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA; McAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Abstract:
Cardiomyocyte cell death is a major contributing factor to various cardiovascular diseases and is therefore an important target for the design of therapeutic strategies. More recently, stem cell therapies, such as transplantation of embryonic or induced pluripotent stem (iPS) cell-derived cardiomyocytes, have emerged as a promising alternative therapeutic avenue to treating cardiovascular diseases. Nevertheless, survival of these introduced cells is a serious issue that must be solved before clinical application. We and others have identified a small non-coding RNA, microRNA-24 (miR-24), as a pro-survival molecule that inhibits the apoptosis of cardiomyocytes. However, these earlier studies delivered mimics or inhibitors of miR-24 via viral transduction or chemical transfection, where the observed protective role of miR-24 in cardiomyocytes might have partially resulted from its effect on non-cardiomyocyte cells. To elucidate the cardiomyocyte-specific effects of miR-24 when overexpressed, we developed a genetic model by generating a transgenic mouse line, where miR-24 expression is driven by the cardiac-specific Myh6 promoter. The Myh6-miR-24 transgenic mice did not exhibit apparent difference from their wild-type littermates under normal physiological conditions. However, when the mice were subject to myocardial infarction (MI), the transgenic mice exhibited decreased cardiomyocyte apoptosis, improved cardiac function and reduced scar size post-MI compared to their wild-type littermates. Interestingly, the protective effects observed in our transgenic mice were smaller than those from earlier reported approaches as well as our parallelly performed non-genetic approach, raising the possibility that non-genetic approaches of introducing miR-24 might have been mediated via other cell types than cardiomyocytes, leading to a more dramatic phenotype. In conclusion, our study for the first time directly tests the cardiomyocyte-specific role of miR-24 in the adult heart, and may provide insight to strategy design when considering miRNA-based therapies for cardiovascular diseases.
Insights
MicroRNA-24 (miR-24) protects cardiomyocytes from cell death after heart attacks. Genetic overexpression of miR-24 in heart cells improved function and reduced damage in mice, validating its therapeutic potential for cardiovascular diseases.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- RNA Therapeutics
Background:
- Cardiomyocyte cell death contributes to cardiovascular diseases, necessitating new therapeutic targets.
- Stem cell therapies show promise but face challenges with transplanted cell survival.
- MicroRNA-24 (miR-24) is a known pro-survival factor for cardiomyocytes, but its specific role in cardiac cells requires further investigation.
Purpose of the Study:
- To investigate the cardiomyocyte-specific effects of microRNA-24 (miR-24) overexpression in vivo.
- To determine if genetic upregulation of miR-24 in cardiomyocytes can protect against myocardial infarction (MI).
- To differentiate the effects of cardiomyocyte-specific miR-24 delivery from broader, non-genetic delivery methods.
Main Methods:
- Generation of a transgenic mouse model with cardiac-specific miR-24 expression driven by the Myh6 promoter.
- Induction of myocardial infarction (MI) in transgenic and wild-type mice to assess cardiac response.
- Evaluation of cardiomyocyte apoptosis, cardiac function, and infarct scar size post-MI.
Main Results:
- Myh6-miR-24 transgenic mice showed no differences from wild-type mice under normal conditions.
- Post-MI, transgenic mice exhibited reduced cardiomyocyte apoptosis, improved cardiac function, and smaller scar size compared to controls.
- The observed protective effects were less pronounced than in previous studies using non-genetic miR-24 delivery methods.
Conclusions:
- This study demonstrates the cardiomyocyte-specific protective role of miR-24 in the adult heart following injury.
- The findings suggest that non-genetic delivery methods may exert broader cellular effects, leading to more significant observed phenotypes.
- This research provides crucial insights for designing targeted microRNA-based therapies for cardiovascular diseases.
